摘要:
Compounds, methods and compositions are provided for inducing natriuresis in a mammal. Methods for isolating and synthesizing the natriuretic compounds are also provided. Therapeutic methods using the natriuretic compounds are also provided. The natriuretic compounds are capable of inducing sodium excretion in a mammal without inducing corresponding prolongated potassium excretion.
摘要:
The present invention is generally related to the discovery of the therapeutic benefit of administering .gamma.-tocopherol and .gamma.-tocopherol derivatives. More specifically, the use of .gamma.-tocopherol and racemic LLU-.alpha., (S)-LLU-.alpha., or .gamma.-tocopherol derivatives as antioxidants and nitrogen oxide scavengers which treat and prevent high blood pressure, thromboembolic disease, cardiovascular disease, cancer, natriuretic disease, the formation of neuropathological lesions, and a reduced immune system response are disclosed.
摘要:
A composition for use in preventing colorectal cancer and other neoplastic diseases, such as breast cancer, includes an enantiomerically stable R-NSAID or a pharmaceutically acceptable salt thereof in an amount effective to elicit a chemoprotective effect. The composition is substantially free of the S-enantiomer of the R-NSAID. Therapeutic use of the composition is accompanied by reduced adverse side effects. A method of treating cystic fibrosis likewise includes the step of administering to a patient in need of such treatment a composition having an effective cystic fibrosis therapeutic amount of an enantiomerically stable R-NSAID or a pharmaceutically acceptable salt thereof, the composition being substantially free of the S-enantiomer of the selected R-NSAID.
摘要:
A compound having the formula I ##STR1## in which R.sub.1, R.sub.2 independently are OH, OOC--R.sub.3 or O--R.sub.3, and R.sub.3 is an unsubstituted or substituted C.sub.1 -C.sub.6 alkyl, alkenyl, alkynyl or phenyl group. The compound is useful as a natriuretic and anti-hypertensive agent.
摘要:
A method of reducing bone loss and promoting bone regrowth, once loss has occurred, particularly alveolar bone loss associated wtih periodontal disease, and a composition useful in the method. The method comprises applying to buccal membranes a therapeutically effective quantity of at least one S enantiomer, generally an S(+) enantiomer, of a nonsteroidal anti-inflammatory drug, such as S(+) flurbiprofen or S(+) ketoprofen. The composition is a formulation which is a toothpaste or which is a mouthwash.
摘要:
A purified naturally occurring natriuretic compound, identified as Natriuretic Hormone, and a method for isolation of the compound. The natriuretic compound has a molecular weight of about 360, a molecular formula of C.sub.21 H.sub.28 O.sub.5 and with a steroidal nucleus. The compound is useful as a diuretic in the treatment of diseases such as heart disease and hypertension.
摘要翻译:纯化的天然存在的利尿钠化合物,被鉴定为利尿钠激素,以及分离化合物的方法。 利钠化合物的分子量为约360,分子式为C 21 H 28 O 5,并具有甾族核。 该化合物可用作利尿剂治疗心脏病和高血压等疾病。
摘要:
Certain new 1-(3',5'-O-Variable-.beta.-D-arabinofuranosyl)-N.sup.4 -.alpha.-aminoacylcytosines, for example, 1-(5'-O-palmitoyl-.beta.-D-arabinofuranosyl)-N.sup.4 -[N.sup..alpha.-[N-(tert-butoxycarbonyl)glycyl]-L-arginyl]cytosine hydrochloride, have been found active against neoplastic cells, viruses, and as immunosuppressants. The 3'-O-, or 5'-O-, variability includes the hydrogen atom and acyl groups. The N.sup.4 -.alpha.-aminoacyl group comprises .alpha.-amino acids, N-protected .alpha.-amino acids, and similar peptidyl sequences of .alpha.-amino acids. Acid addition salts are an embodiment of the invention.
摘要:
This invention relates to the use of enantiomerically pure R-NSAIDs for the treatment of inflammation. Preferably, the R-NSAID used is R-flurbiprofen and is administered in a dose of at least 5 milligrams per kilogram of body weight per day. The anti-inflammatory action of R-NSAIDs is due to their ability to interfere with the biosynthesis of COX-2 by inhibiting COX-2 mRNA synthesis, rather than by just blocking the action of the enzyme itself. In order to effect the inhibition of COX-2 mRNA synthesis, the R-NSAID must be present at relatively high doses. Because the R-NSAID is selective in its action, that is, it does not inhibit either COX-1 mRNA synthesis or the COX-1 enzyme itself, it can be administered in the required high doses because the tissue protective effects of prostaglandins made through the COX-1 pathway are not interfered with.
摘要:
The present invention is generally related to the discovery of the therapeutic benefit of administering &ggr;-tocopherol and &ggr;-tocopherol derivatives. More specifically, the use of &ggr;-tocopherol and racemic LLU-&agr;, (S)-LLU-&agr;, or &ggr;-tocopherol derivatives as antioxidants and nitrogen oxide scavengers which treat and prevent high blood pressure, thromboembolic disease, cardiovascular disease, cancer, natriuretic disease, the formation of neuropathological lesions, and a reduced immune system response are disclosed.
摘要:
The present invention is generally related to the discovery of the therapeutic benefit of administering &ggr;-tocopherol and &ggr;-tocopherol derivatives. More specifically, the use of &ggr;-tocopherol and racemic LLU-&agr;, (S)-LLU-&agr;, or &ggr;-tocopherol derivatives as antioxidants and nitrogen oxide scavengers which treat and prevent high blood pressure, thromboembolic disease, cardiovascular disease, cancer, natriuretic disease, the formation of neuropathological lesions, and a reduced immune system response are disclosed.